Alex Hemeryck

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi request reprint Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update
    Alex Hemeryck
    Heymans Institute of Pharmacology, Ghent University, Faculty of Medicine and Health Sciences, Belgium
    Curr Drug Metab 3:13-37. 2002
  2. pmc Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model
    L Mark Kao
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 50:3535-42. 2006
  3. ncbi request reprint Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib
    Alex Hemeryck
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, A Division of Janssen Pharmaceutica N V, Beerse, Belgium
    Cancer Chemother Pharmacol 60:777-87. 2007
  4. doi request reprint In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping
    Marc Vermeir
    Johnson and Johnson Pharmaceutical Research and Development J and JPRD, A Division of Janssen Pharmaceutica N V, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Biochem Pharmacol 77:1642-54. 2009

Detail Information

Publications4

  1. ncbi request reprint Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update
    Alex Hemeryck
    Heymans Institute of Pharmacology, Ghent University, Faculty of Medicine and Health Sciences, Belgium
    Curr Drug Metab 3:13-37. 2002
    ..In some cases, therapeutic drug monitoring can be useful. Equally well, an SSRI with limited interaction potential may be selected to treat depression in patients that receive other medications...
  2. pmc Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model
    L Mark Kao
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 50:3535-42. 2006
    ..These data demonstrate that a humanized dosing regimen of levofloxacin was effective in preventing morbidity and mortality from inhalational anthrax in rhesus monkeys and did not select for resistance...
  3. ncbi request reprint Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib
    Alex Hemeryck
    Global Preclinical Development, Johnson and Johnson Pharmaceutical Research and Development, A Division of Janssen Pharmaceutica N V, Beerse, Belgium
    Cancer Chemother Pharmacol 60:777-87. 2007
    ..The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus) administration with (14)C-labelled bortezomib (VELCADE) (0.2 mg/kg; 0.28 MBq./kg)...
  4. doi request reprint In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping
    Marc Vermeir
    Johnson and Johnson Pharmaceutical Research and Development J and JPRD, A Division of Janssen Pharmaceutica N V, Turnhoutseweg 30, B 2340 Beerse, Belgium
    Biochem Pharmacol 77:1642-54. 2009
    ..In monkey and human liver microsomes, trabectedin was not substantially metabolized by glucuronidation...